10.1016/s0891-5849(02)01006-7 73 KamoshitaM.OzawaY.KubotaS.MiyakeS.TsudaC.NagaiN.et al (2014)
order: 100 pieces Guangdong Tinsun Biotechnology Co.,Ltd
Another novel humanized anti-ASCT2 monoclonal antibody, KM8094, exhibited anti-tumor activity in GC patient-derived xenografts
Intravenous protocols require provider supervision due to infusion risks, potential reactions, and need for ongoing monitoring of therapeutic response
IMPORTANT PRESCRIBER & PATIENT NOTICE This preparation is compounded only when the prescribing practitioner documents that the FDA-approved product does not meet the patients medical needs (e.g., different strength, excipient profile, or delivery route)
Plant Cell Environ 40(8):12811295